Obeldesivir

obeldesivir is an oral antiviral being tested as post-exposure prophylaxis in the first authorised therapeutic trial for Bundibugyo ebolavirus. In the trial protocol launched in June 2026, it is assigned to people who have been exposed to a confirmed Bundibugyo patient but have not yet developed symptoms. WHO Disease Outbreak News 607 noted that obeldesivir differs from the drugs named in the 28 May expert advisory, making it a notable change to the originally-anticipated treatment protocol.

Chemically, obeldesivir is a prodrug: an inactive compound the body converts into GS-441524, a nucleoside analogue that the virus cannot easily replicate around. GS-441524 is the parent nucleoside of remdesivir, the intravenous antiviral that was evaluated but not prioritised in earlier stages of the trial design. The oral route matters in a conflict-zone outbreak: post-exposure prophylaxis taken as a tablet is FAR easier to administer in field conditions than an intravenous drip, and extends coverage to contacts who cannot reach a treatment centre.

obeldesivir is investigational and not approved for any indication. Its significance here is practical: it provides a prophylactic option for healthcare workers and confirmed contacts in a setting where the virus kills and no licensed Bundibugyo countermeasure exists. The trial data it generates in this outbreak will determine whether it advances towards regulatory review for haemorrhagic fever indications.